AQP4-NMOSD vs MOGAD: Findings from a Study of Human Patients
The study compared profiles of 453 AQP4-NMOSD patients with 2533 MOGAD patients. AQP4-NMOSD patients were older and mostly female, showing a higher autoimmune burden with conditions like systemic lupus erythematosus and rheumatoid arthritis. They exhibited reduced serum IgG levels post-diagnosis. The COVID-19 era revealed persistent high comorbidity odds in AQP4-NMOSD, whereas MOGAD had specific comorbidity accrual.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
Understanding the differences in autoimmune profiles between AQP4-NMOSD and MOGAD aids in recognizing disease mechanisms and potential patient management strategies. High comorbidities in AQP4-NMOSD may impact patient care and quality of life.
What this does not prove
Multiple sclerosis was excluded from the study, limiting broader comparison. While immune lab markers were analyzed, no specific efficacy results were reported, leaving uncertainty about clinical implications.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 2986 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-17
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Includes 2533 MOGAD and 453 AQP4-NMOSD patients
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceAutoimmune comorbidity profiles in MOGAD and AQP4-NMOSD: a real-world evidence study of top 10 autoimmune disorders across the pre- and post-COVID-19 eras. ↗DOI: 10.1016/j.msard.2026.108003
Supporting passages (8)
sample sizeAntibody-confirmed cohorts included 2533 MOGAD and 453 AQP4-NMOSD patients (multiple sclerosis was strictly excluded).
publication datePublication date: 2026-10-17
populationAntibody-confirmed cohorts included 2533 MOGAD and 453 AQP4-NMOSD patients (multiple sclerosis was strictly excluded).
findingsRESULTS: AQP4-NMOSD patients were older and predominantly female compared to those with MOGAD. AQP4-NMOSD demonstrated a substantially higher baseline systemic autoimmune burden, including systemic lupus erythematosus (16%vs 1%), other connective tissue involvement (12%vs 5%), rheumatoid arthritis (6%vs 2%), and autoimmune gastrointestinal disease. Marked serum IgG reduction and post-diagnosis autoantibody titer resolution occurred predominantly in AQP4-NMOSD. COVID-era comparisons revealed persistent, high comorbidity odds in AQP4-NMOSD alongside selective temporal accrual of connective tissue, vascular, and thyroid comorbidities within MOGAD.
limitationsTitle: Autoimmune comorbidity profiles in MOGAD and AQP4-NMOSD: a real-world evidence study of top 10 autoimmune disorders across the pre- and post-COVID-19 eras.
peer reviewedPublication types: Journal Article
study designMETHODS: We conducted a retrospective cohort study using the TriNetX Global Research Network (2015-2025).
subjectsAntibody-confirmed cohorts included 2533 MOGAD and 453 AQP4-NMOSD patients (multiple sclerosis was strictly excluded).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.